Cosman F, Shen V, Herrington B, Lindsay R
Regional Bone Center, Helen Hayes Hospital, West Haverstraw, New York 10993.
J Clin Endocrinol Metab. 1991 Dec;73(6):1345-51. doi: 10.1210/jcem-73-6-1345.
Alterations in the sensitivity of the parathyroid gland to both stimulative and suppressive stimuli may be partially responsible for skeletal changes that occur with age, estrogen deficiency, osteoporosis, and estrogen treatment of osteoporosis. We sought to define the changes in intact PTH-(1-84) secretion in normal premenopausal and postmenopausal, osteoporotic and estrogen-treated osteoporotic women during the infusion of human (h) PTH-(1-34). hPTH-(1-34) was infused at 0.55 U/kg.h for 24 h, with serum sampling every 4 h. Serum was analyzed for calcium (ionized and total), hPTH-(1-34), and PTH-(1-84). Basal chemistries were no different among groups, except for serum phosphorus, which was highest in osteoporotic women (1.31 vs. 1.07 mmol/L in premenopausal; P less than 0.02), and hPTH-(1-34), which was slightly higher in normal postmenopausal women (19.31 vs. 13.24 ng/L in estrogen treated; P less than 0.02). No differences in PTH-(1-84) were found among groups. hPTH-(1-34) rose similarly in all patient groups, while the calcemic response was somewhat more sluggish in estrogen-treated women, although statistically significant differences were not found. PTH-(1-84) declined rapidly in all patient groups, although estrogen-treated women had a smaller maximal decrease in PTH-(1-84), and the slope of the decremental change in PTH-(1-84) was lower in estrogen-treated women than in osteoporotic or normal postmenopausal women. Untreated osteoporotic women had less suppression of PTH-(1-84) than normal postmenopausal women at every calcium level. Estrogen treatment decreases the calcemic effects of infused hPTH-(1-34) and at the same time reduces calcium-induced suppression of parathyroid secretion. It is possible that such changes in the set-point of the gland contribute to the alterations in bone turnover that result in osteoporosis and the mechanisms by which estrogen prevents bone loss.
甲状旁腺对刺激和抑制性刺激的敏感性改变可能部分导致了随年龄增长、雌激素缺乏、骨质疏松以及雌激素治疗骨质疏松时出现的骨骼变化。我们试图确定在输注人(h)PTH-(1-34)期间,正常绝经前和绝经后、骨质疏松以及接受雌激素治疗的骨质疏松女性中完整PTH-(1-84)分泌的变化。以0.55 U/kg·h的速率输注hPTH-(1-34),持续24小时,每4小时采集一次血清样本。分析血清中的钙(离子钙和总钙)、hPTH-(1-34)和PTH-(1-84)。除血清磷外,各组的基础化学指标无差异,血清磷在骨质疏松女性中最高(绝经前为1.31 mmol/L,而绝经前为1.07 mmol/L;P<0.02),hPTH-(1-34)在正常绝经后女性中略高(接受雌激素治疗的为19.31 ng/L,而雌激素治疗的为13.24 ng/L;P<0.02)。各组之间未发现PTH-(1-84)有差异。所有患者组中hPTH-(1-34)的升高情况相似,而接受雌激素治疗的女性的血钙反应略显迟缓,尽管未发现统计学上的显著差异。所有患者组中PTH-(1-84)均迅速下降,尽管接受雌激素治疗的女性中PTH-(1-84)的最大降幅较小,且接受雌激素治疗的女性中PTH-(1-84)递减变化的斜率低于骨质疏松或正常绝经后女性。在每个钙水平上,未经治疗的骨质疏松女性对PTH-(1-84)的抑制作用均低于正常绝经后女性。雌激素治疗可降低输注的hPTH-(1-34)的血钙效应,同时减少钙诱导的甲状旁腺分泌抑制。甲状旁腺设定点的这种变化可能导致骨转换改变,进而导致骨质疏松,以及雌激素预防骨质流失的机制。